ConsoneAI, "Predicting Toxicity, Protecting Lives"
What sets us apart?
ConsoneAI use computational models and AI technology to dramatically accelerate the new drug development process by reducing, refining and replacing (NC3Rs) the need for animal testing, and helping to develop safer drugs more quickly and cost effectively.
​
Our platform, DioScor, integrates our bespoke advanced machine learning algorithms and vast datasets to predict toxicological outcomes ​across multiple animal species, non-human primates, through to men and women, with high precision.
Revolutionary Innovation
Key features include:
Organ-Specific and Demographic-Specific Predictions:
-
Our Proof of Concept created with an Innovate UK Fast Start grant created results for foetal, respiratory and sense organs.
-
Capable of predicting toxicity for specific organs.
-
Enhanced Prediction Models: Offers detailed toxicity predictions by gender and age.
What we do
What we cover in toxicology predictions:
-
General molecule toxicity
-
Safety pharmacology
-
Genotoxicity
-
Reproductive toxicity
-
Carcinogenicity studies
-
Others: e.g., impurity qualification toxicology studies
Excellence
Drug safety and drug toxicity is a complex process, animal trails may not give any systematic indication to why the toxicity has occurred.
​
Our commitment to excellence reaches all aspects of our product development through to patient safety. ​
Meet the Team
ConsoneAI: founded in 2020 and has core intellectual team driving product development, innovation and business model. Our cohesive team consists of CEO, COO and a CTO whose combined strengths and experience bring and united business focus. We have secured a number of key individuals for our scientific advisory board, who are keen to offer technical insights and support our development..
Bruce Swan
Co-founder and Chief Operating Officer (COO) of ConsoneAI. Bruce has over 30 years' scientific experience having worked within Sanofi and GSK in laboratory and technical roles. He moved into commercial roles covering business development, client strategy, HR and project management. He is a strongly driven and motivated individual who enjoys interacting with clients/businesses and developing new commercial opportunities. Through the skills of developing relationships, he has a proven ability to grasp new concepts, technology and develop innovative and creative solutions. As COO of ConsoneAI, he is the backbone of the company, direction and delivery.
​
Mo Kosar
Co-founder and Chief Executive Officer (CEO) of a ConsoneAI, reducing the requirements of animal testing during early drug development. Mo holds a double degree in Mathematics and Biomedical Science graduate. She designed the clinical trials which gained the research Ethics committee approval. The product development has provided her with hands on experience with formulation, materials chemistry, biochemistry, toxicology, and microbiology. Mo had a successful 8 year career in direct sales, with senior positions selling hardware, software, and services enterprise solutions to international corporate and small to medium businesses. Mo is the life of the product vision, values and direction.
Dr. Miguel Pereira
Chief Technology Officer (CTO) - Miguel has a PhD in Data Science and Biostatistics. Originally trained as medical physician, he has over 8 years' experience working in data analytics, machine and deep learning. He has worked and led projects involved in the application and development of statistical methodologies to multiple types of epidemiological and healthcare data: clinical trials, large-scale epidemiological data, omics data (e.g., NGS, GWAS). He also creates and deliveres educational content in data science and biostatistics.
Alex Fraser
Machine learning engineer with experience in Bioinformatics and Cheminformatics. Alex's previous academic experience in the biological sciences, and industry experience in Healthtech, led him to pursue a career in computational biology. Previous projects include investigating the use of explainable AI in drug response prediction in cancer, as well as the application of machine learning in IBD diagnosis.
ConsoneAI - Scientific Advisory Board
Dedication. Expertise. Passion.
Partnership
Time to Engage
ConsoneAI need partnerships and collaborations to put the client focus on developing successful drug development pipelines and ensuring animal testing is reduced but ensuring Patient Safety.
Sustainability & Ethical
Sustainability and Ethical Responsibility: By minimizing animal testing and focusing on safer drug development practices, ConsoneAI supports sustainability and ethical responsibility in the pharmaceutical industry.
Your Drug asset pipeline
Data-Driven Insights: The platform leverages advanced algorithms and vast datasets to provide comprehensive toxicity profiles, empowering researchers with data-driven insights for better decision-making.
Who can benefit from DioScor?
DioScor has been designed to aid the decision making within Pharmaceutical, Biotech, Academia, Investors including acquisition of drug assists. Working across all aspects of the discovery, development and regulatory functions.
Investment and collaborations
